Callio Therapeutics

Multi-payload antibody-drug conjugates

Seattle, United States · Founded 2025 · $187.0M raised

Employees
1–10
Founded
2025
Business Model
B2B
Total Funding
$187.0M
Last Round
$187.0M Series AMar 2025
Rounds
1

About

Callio Therapeutics is a clinical-stage biotechnology company developing next-generation multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Founded in 2025 and headquartered in Seattle and Singapore, the company's lead program CLIO-8221 is a dual-payload ADC targeting HER2-expressing solid tumors that delivers a topoisomerase 1 inhibitor and an ATR inhibitor simultaneously to overcome resistance to existing ADC therapies.

Summary

Callio Therapeutics is a Biotech company based in Seattle, United States, founded in 2025. It has raised $187.0M in total across 1 round, most recently a $187.0M Series A round in Mar 2025.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2025
$187.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Callio Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/callio-therapeutics"><img src="https://indexed.vc/api/badge/company/callio-therapeutics" alt="Callio Therapeutics on Indexed.vc" width="260" height="76" /></a>